Advertisement

Expert Point of View: Renata Ferrarotto, MD


Advertisement
Get Permission

Renata Ferrarotto, MD

Renata Ferrarotto, MD

Renata Ferrarotto, MD, Associate Professor, and Director of Head and Neck Clinical Research at The University of Texas MD Anderson Cancer Center, Houston, called the efficacy results with cabozantinib plus atezolizumab in recurrent or metastatic head and neck squamous cell carcinoma “encouraging” given the difficult-to-treat patient population.

“[These results] are particularly noteworthy considering that all patients in the COSMIC-021 trial were platinum-pretreated, with a median number of prior lines of therapy of 2.5, patients were not selected based on PD-L1 status, and 30% had received a prior PD-1 inhibitor,” Dr. Ferrarotto told The ASCO Post.

“The results of this study in a heavily pretreated patient population, together with the data reported earlier this year at the 2022 ASCO Annual Meeting with cabozantinib plus pembrolizumab in the first-line setting, support further studies of cabozantinib and PD-1/PD-L1 inhibitors in head and neck squamous cell carcinoma,” Dr. Ferrarotto continued. “Identifying biomarkers of clinical benefit from the combination vs single-agent checkpoint inhibitor therapy will be important for patient selection.” 

DISCLOSURE: Dr. Ferrarotto reported no conflicts of interest.


Related Articles

Cabozantinib Plus Atezolizumab Warrants Further Study in Treatment of Advanced Head and Neck Cancer

A challenging patient population with advanced head and neck cancer may have a new treatment option, according to data presented during the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting.1

Results from Cohort 17 of the COSMIC-021 study showed that the combination of the kinase...

Advertisement

Advertisement




Advertisement